ProfoundBio (Suzhou) Co., Ltd. announced that it has received $112 million in a round of funding led by new investor Ally Bridge Group on February 13, 2024. The transaction included participation from new investors Nextech Invest Ltd., RA Capital Management, L.P., OrbiMed Advisors LLC, Surveyor Capital Management, Piper Heartland Healthcare Capital, LLC, LifeSci Venture Partners, Janus Henderson Investors, Medicxi, Logos Capital, Octagon Capital, accounts advised by T. Rowe Price Group, Inc., returning investors Lyfe Capital, Eli Lilly Investment Consulting (Shanghai) Co., Ltd. Andrew Lam, Eric Dobmeier and Enoch Kariuki will join board of directors of the company. This funding round was over-subscribed.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
114.4 USD | +1.50% | +2.80% | +6.19% |
May. 10 | Goldman Sachs Adjusts Price Target on T. Rowe Price Group to $110 From $112, Keeps Sell Rating | MT |
May. 10 | T. Rowe Price Group's Preliminary Assets Under Management Decline in April | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.19% | 25.54B | |
-1.09% | 119B | |
+14.62% | 67.3B | |
+18.97% | 63.09B | |
+12.10% | 43.64B | |
+14.61% | 43.24B | |
+22.22% | 35.8B | |
-1.16% | 23.06B | |
+7.02% | 19.73B | |
+2.25% | 17.65B |
- Stock Market
- Equities
- TROW Stock
- News T. Rowe Price Group Inc.
- ProfoundBio Co., Ltd. announced that it has received $112 million in funding from a group of investors